Agar Capillary Clonogenic Microassays for Cellular Immunocytotoxic Activities in Human Leukaemia and Lymphoma

References

• Gutterman J. U., Hersh E. M., Rodriguez V., McCredie K. B., Mavligit G., Reed R., Burgess M. A., Smith T., Gehan E., Bodey G. P., Friereich E. J. Chemoimmu-notherapy of adult acute leukemia. Prolongation of remission in myeloblastic Leukemia with BCG. Lancet 1974; ii: 1405–-1409
   Google Scholar
• Medical Research Council. Immunotherapy of acute myeloid leukaemia. British Journal of Haemalology 1978; 37: 1–14
   Web of Science ®Google Scholar
• Vogler W. R. Results of randomised trials of immunotherapy for acute leukemia. Cancer Immunology and Immunotherapy 1981; 9: 15–21
   Web of Science ®Google Scholar
• Hoerni B., Ravaud A., Eghbali H., Hoerni-Simon G. Adjuvant therapy by BCG of Non-Hodgkin's malignant lymphomas in a controlled trial: an update. British Journal of Haemalology 1989; 71: 161–163
   PubMed Web of Science ®Google Scholar
• Reizenstein P. Adjuvant immunotherapy with BCG of acute myeloid leukaemia: a 15-year follow up. British Journal of Haematology 1990; 75: 288–289
   PubMed Web of Science ®Google Scholar
• Foon K. A., Sherwin S. A., Abrahams P. G., et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leucocyte interferon. New England Journal of Medicine 1984; 311: 1148–1152
   PubMed Web of Science ®Google Scholar
• Foon K. A., Bottino G. C., Fer M. F., et al. Phase II trial of recombinant leucocyte alpha-interferon in patients with advanced chronic lymphocytic leukemia. American Journal of Medicine 1985; 78: 216–220
   PubMed Web of Science ®Google Scholar
• Worman C. P., Catovsky D., Bevan P. C., et al. Interferon-alpha is effective in hairy cell leukemia. British Journal of Haematology 1985; 69: 979–983
   Google Scholar
• Horning S. H., Merigan T. E., Krown S. E., et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Cancer 1985; 56: 1305–1310
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Hersh E. M., Manning J., et al. Treatment o'f Hairy cell Leukemia with recombinant alpha-interferon. Blood 1986; 68: 493–497
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Sanders J. E., et al. Prophylactic use of human leucocyte interferon after allogeneic marrow transplantation. Annals of Internal Medicine 1987; 107: 809–816
   PubMed Web of Science ®Google Scholar
• Leavitt R. D., Ratanatharathorn V., Ozer H., et al. Alpha-interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Seminars in Oncology 1987; 14: 18–23
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarijian H. M., McCredie K. B., et al. Clinical investigation of alpha-interferon in chronic myeloid leukemia. Blood 1987; 69: 1280–1288
   PubMed Web of Science ®Google Scholar
• Galvani D. W., Nethersell A. B. W., Cawley J. C. Interferon in myelodysplasia: clinical observations and effects on NK cells. Leukemia Research 1988; 12: 257–262
   PubMed Web of Science ®Google Scholar
• Hellström E., Robert K-H., Gahrton G., et al. Therapeutic effects of low dose cytosine arabinoside, alpha-interferon, 1,25-dihydroxyvitamin D3 and retinoic acid in acute Leukemia and myelodysplastic syndrome. European Journal of Haematology 1988; 40: 449–459
   PubMed Web of Science ®Google Scholar
• Stotnicki A. B., Wolsak-Smolen T., Bicharski J., et al. Human recombinant interferon alpha in the treatment of patients with Hairy cell leukemia. Cancer Detection and Prevention 1988; 12: 511–522
   PubMedGoogle Scholar
• Ziegle-Heitbroch H. W. L., Schlag R., Flige D., Thiel E. Favourable response of early stage B-cell patients to interferon-alpha. Blood 1989; 73: 1426–1430
   PubMed Web of Science ®Google Scholar
• Thompson J. A., Kidd P., Rubin E., et al. Very low dose alpha-interferon for the treatment of hairy cell leukemia. Blood 1989; 73: 1440–1443
   PubMed Web of Science ®Google Scholar
• Steger G. G., Dittrich C., Chott A., Derfler K., Schwarzmeier J. D. Long-term remission in a patient with erythroLeukemia following interferon-alpha treatment. Journal of Biological Response Modifiers 1989; 8: 351–354
   PubMedGoogle Scholar
• Berman E., Heller G., Kempin S., et al. Incidence of response and long term follow-up in patients with Hairy cell Leukemia treated with recombinant interferon-alpha. Blood 1990; 75: 839–845
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E., Messner H. The maintenance of busulphan-induced remissions in chronic granulocytic Leukemia with interferon alpha. British Journal of Cancer 1990; 61: 895–898
   PubMed Web of Science ®Google Scholar
• Ogura H., Tani K., Kozai Y., Watari K., Kodo H., Ozawa K., Asano A., Takaku F. Effect of interferon-alpha in patients with chronic myelogenous Leukemia in the accelerated phase: cytogenetic and molecular studies. Japanese Journal of Cancer 1990; 81: 682–686
   PubMedGoogle Scholar
• Herrmann F., Jonas D., Helfrich S. G., Lindemann A., Schleiermacher E., Mertelsmann R. Interferon-alpha 2c in chronic myelogenous leukaemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon-gamma. Blut 1990; 61: 226–231
   PubMedGoogle Scholar
• Golomb H. M., Fefer A., Golde D. W., et al. Survival experience of 195 patients with hairy cell Leukemia treated in a multi-institutional study with interferon-alpha. Leukemia and Lymphoma 1991; 4: 99–102
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Anderson S. A., Tuttle R. L., et al. A randomized comparison of two doses of human lympho-blastoid interferon-alpha in Hairy cell leukemia. Blood 1991; 78: 3133–3141
   PubMed Web of Science ®Google Scholar
• Aul C., Gattermann N., Schneider W. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha. European Journal of Haematology 1991; 46: 11–16
   PubMed Web of Science ®Google Scholar
• Klingemann H. G., Grigg A. P., Boyd K. W., Barnett M. J., Eaves A. C., Reece D. E., Shepherd J., Philips G. L. Treatment with recombinant interferon-alpha early after bone marrow transplantation in patients at high risk of relapse. Blood 1991; 78: 3306–3311
   PubMed Web of Science ®Google Scholar
• Yataganas X., Eliopoulos G., Koulocheri S., Viniou N., Plata E., Panagiotidis P., Vayopoulos G., Meletis J., Fessas P. The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome. Annals of Hematology 1991; 62: 225–229
   PubMed Web of Science ®Google Scholar
• Ochs J., Brecher M. L., Mahoney D., Vega R., Pollock B. H., Buchanan G. R., Whitehead V. M., Ravindranath Y., Freeman A. L. Recombinant interferon alfa given before and in combination with standard chemotherapy in children with acute lymphoblastic Leukemia in first marrow relapse: a pediatric oncology group pilot study. Journal of Clinical Oncology 1991; 9: 777–782
   PubMed Web of Science ®Google Scholar
• Thaler J., Kuhr T., Gastl G., et al. Recombinant human interferon-alpha in Ph-positive chronic myeloid leukemia. Results of a multicenter phase II study. Deutsche Medizin. Wochenschrift 1991; 116: 721–728
   PubMed Web of Science ®Google Scholar
• Guilhot F., Dreyfus B., Brizard A., Huret J. L., Tanzer J. Cytogenetic remissions in chronic myelogenous Leukemia using recombinant human alpha 2b interferon and hydroxyurea with or without low dose cytosine arabinoside. Leukaemia and Lymphoma 1991; 4: 49–55
   PubMed Web of Science ®Google Scholar
• Dow L. W., Raimondi S. C., Culbert S. J., Ochs J., Kennedy W., Pinkel D. P. Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukaemia. Cancer 1991; 68: 1678–1684
   PubMed Web of Science ®Google Scholar
• Montserrat E., Villamor N., Urbano-Ispizue A., Ribera J. M., Lazano M., Vives-Corrons J. L., Rozman C. Treatment of early stage-B chronic lymphocytic leukaemia with alpha-2b interferon after chlorambucil reduction of the tumour mass. Annals of Haematology 1991; 63: 15–19
   PubMed Web of Science ®Google Scholar
• Hassan H. T., Zyada L. E. 1992, Treatment with interferon-alpha plus low dose cytarabine with or without hydroxyurea in acute monoblastic leukaemia. Haematology Reviews and Communications6, in press
   Google Scholar
• Kay N. E., Olcen M. M., Mazza J. J., Bradley E. C. Evidence for tumour reduction in refractory or relapsed B-chronic lymphocytic Leukemia patients with infusional interleukin-2. Nouvelle Revue Francaise d'Hematologie 1988; 30: 475–478
   PubMedGoogle Scholar
• Nasr S., McKolanis J., Ray P., Findley H., Hnath R., Waldrep K., Ragab A. H. A phase I study of interleukin-2 in children with Leukemia and evaluation of clinical and immunologic status during therapy. Cancer 1989; 64: 783–788
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Brenner M. K., Heslop H. E., Bianchi A. C. M., Bello-Fernandez C., Mehta A. B., Newland A. C., Galazka A. R., Scott E. M., Hoffbrand A. V., Prentice H. G. A phase I clinical trial of recombinant human interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. British Journal of Cancer 1989; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Allison M. A. K., Jones S. E., McGuffey P. Phase II of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic Leukemia and selected solid tumours. Journal of Clinical Oncology 1989; 7: 75–80
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Annals of Surgery 1989; 210: 474–484
   PubMed Web of Science ®Google Scholar
• Meloni G., Foa R., Tosti S., Vignetti M., Gavosto F., Mandelli F. Interleukin-2 in the treatment of chronic myeloid leukaemia after lymphoid blast crisis: a pilot study. Haematologica 1990; 75: 502–505
   PubMedGoogle Scholar
• Foa R., Fierro M. T., Tosti S., Meloni G., Gavosto F., Mandelli F. Induction and persistence of complete remission in a resistance acute myeloid leukaemia patient after treatment with recombinant interleukin-2. Leukemia and Lymphoma 1990; 1: 113–117
   PubMedGoogle Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Guarini A., Cardona S., Gillio T. S., Gavosto F., Mandelli F. Treatment of residual disease in acute Leukemia patients with interleukin-2 (IL-2): clinical and biological findings. Bone Marrow Transplantation 1990; 6(suppl. 1)98–102
   PubMedGoogle Scholar
• Sykes M., Romick M. L., Sachs D. H. Interleukin-2 prevents graft-versus host disease while preserving the graft-versus Leukemia effect of all allogeneic T cells. Proceedings of National Academy of Science USA 1990; 87: 5633–5637
   PubMed Web of Science ®Google Scholar
• Pais R. C., Ingrim N. B., Garcia M. L., Abdel-Mageed A., McKolanis J., Ingrim M. E., Hnath R. S., Ziegler K., Ragab A. H. Pharmacokinetics of recombinant human interleukin-2 in children with malignancies: a pediatric oncology group study. Journal of Biological Response Modifiers 1990; 9: 517–521
   PubMedGoogle Scholar
• Hamblin T. J., MacDonald D., Jiang Y., Gordon A. A., Mahendra P., Oskam R., Palmer P. A., Franks C. R., Barrett A. J. Recombinant interleukin-2 for acute myeloid leukaemia in first complete remission: a pilot study. Leukemia Research 1990; 57: 249–266, 1990, Current Studies in Hematology & Blood Transfusion 14, 967, 972
   Google Scholar
• Blaise D., Olive D., Stoppa A. M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Franks C., Philip T., Maraninchi D. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1098
   PubMed Web of Science ®Google Scholar
• Higuchi C. M., Thompson J. A., Peterson F. B., Buckner D., Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous marrow transplantation of hematologic malignancies. Blood 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Lim S. H., Worman C. P., Callaghan T., Jewell A., Smith M. P., Goldstone A. Continuous intravenous infusion of high dose recombinant interleukin-2 for advanced lymphoma–a phase II study. Leukemia Research 1991; 15: 435–440
   PubMed Web of Science ®Google Scholar
• Margolin K. A., Aronson F. R., Sznol M., Atkins M. B., Ciobanu N., Fisher R. I., Weiss G. R., Doroshow J. H., Bar M. H., Hawkins M. J. Phase II trial of high-dose interleukin-2 and LAK cells in Hodgkin's disease and Non-Hodgkin's lymphoma. Journal of Immunotherapy 1991; 10: 214–220
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Vaickus L., Freidman N., Goldrosen M. H., Watanabe H., Rahman R., Arbuck S. G., Sweeney J., Vesper D., Henderson E. D. Interleukin-2/ LAK cell therapy of non-Hodgkin's and Hodgkin's lymphoma. Journal of Immunotherapy 1991; 10: 141–146
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Duncombe A. S., Reittie J. E., Bello-Fernandez C., Gottlieb D. J., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. Interleukin-2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. British Journal of Haematology 1991; 77: 237–244
   PubMed Web of Science ®Google Scholar
• Lim S. H., Callaghan T., Goldstone A. Thyroid disorders in 2 cases of acute myeloid Leukemia following treatment with recombinant human interleukin-2 infusion. Acta Haematologia 1991; 85: 49–50
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Schachner J. R., Huh J. O., McCredie K. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous Leukemia after infusion with interleukin-2. American Journal of Hematology 1991; 37: 88–99
   PubMed Web of Science ®Google Scholar
• Tourani J-M., Levy V., Briere J., Levy R., Franks C., Andrieu J.-M. Interleukin-2 therapy for refractory and relapsing lymphomas. European Journal of Cancer 1991; 27: 1676–1680
   PubMed Web of Science ®Google Scholar
• Lim S. H., Worman C., Jewell A., Tsakona C., Giles F. J., Goldstone A. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias. Cancer Immunology Immunotherapy 1991; 33: 133–137
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F., Mandelli F. Treatment of acute myeloid Leukemia patients with recombinant interleukin-2; a pilot study. British Journal of Haematology 1991; 77: 491–496
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens M., Brandely D., Olive M., Lopez D., Sainty G., Mark A. M., Stoppa A. M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Nercend T., Sbahoun G., Carcassonne Y. High-dose recombinant interleukin-2 and acute myeloid Leukemia in relapse. Blood 1991; 78: 2181–2187
   Google Scholar
• Ritz J., Pesando J. M., Sallen S. E., Clavell L. A., Notis-McConarty J., Rosenthal P., Schlossman S. F. Serotherapy of acute lymphoblastic Leukemia with monoclonal antibody. Blood 1981; 58: 141–147
   PubMed Web of Science ®Google Scholar
• Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine 1982; 306: 517–523
   PubMed Web of Science ®Google Scholar
• Linch D. C., Beverly P. C. L., Newland A., Turnbull A. Treatment of low grade T cell proliferation with monoclonal antibody. Clinical Experimental Immunology 1983; 51: 133–140
   PubMed Web of Science ®Google Scholar
• Levy R., Miller R. A., Stratte P. T., Maloney D. G., Link M. P., Meeker T. C., Oseroff A., Thielemans K., Warnke R. Therapeutic trials of monoclonal antibody in Leukemia and lymphoma: biological considerations. In:. Monoclonal Antibodies and Cancer, B. Boss, R. Langman, I. Trowbridge, R. Dulbecco. Academic Press, New York: 1983
   Google Scholar
• Foon K. A., Schroff R. W., Mayer D., Sherwin S. A., Oldham R. K. Monoclonal antibody therapy of chronic lymphocytic Leukemia and cutaneous T-cell lympho-ma: preliminary observations. In:. Monoclonal Antibodies and Cancer, B. Boss, R. Langman, I. Trowbridge, R. Dublecco. Academic Press, New York: 1983
   Google Scholar
• Dillman R. O., Shawler D. L., Dillman J. B., Royston I. Therapy of chronic lymphocytic Leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Journal of Clinical Oncology 1984; 2: 881–887
   PubMed Web of Science ®Google Scholar
• Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Per M., Ochs J., Bottino G. C., Sherwin S. A., Carlo D. J., Heberman R. B., Oldham R. K. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085–1090
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Lowder J. N., Maloney D. G., Miller R. A., Thielemanns K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349–1356
   PubMed Web of Science ®Google Scholar
• Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Thomas E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B CLL lymphomas. Blood 1987; 69: 584–589
   PubMed Web of Science ®Google Scholar
• Hamblin T. J., Cattan A. R., Glennie M. J., MacKenzie M. R., Stevenson F. K., Watts H. F., Stevenson G. T. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 1987; 69: 790–798
   PubMed Web of Science ®Google Scholar
• Hale G., Clark M. R., Marcus R., Winter G., Dyer M. J. S., Philips J. J., Reichmann L., Waldmann H. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody Campath-IH. Lancet 1988; ii: 1394–-1396
   Google Scholar
• Waldmann T. A., Goldman C. K., Bongiovanni K. F., Sharrow S. O., Davey M. P., Cease K. B., Greenberg S. J., Longo D. L. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell Leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805–1809
   PubMed Web of Science ®Google Scholar
• Brown S. L., Miller R. A., Horning S. J., Czerwinski D., Hart S. M., McElderry R., Basham T., Warnke R. A., Merigan T. C., Levy R. Treatment of B-cell lymphomas with idiotype antibodies alone and in combination with alpha-interferon. Blood 1989; 73: 651–658
   PubMed Web of Science ®Google Scholar
• Allebes W., Knops R., Bontrop R. E., Otting N., Raemakers J., Haanen C., Capel P. J. Phenotypic and functional changes of tumour cells from patients treated with monoclonal and anti-idiotypic antibodies. Scandinavian Journal of Immunology 1990; 32: 441–449
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., George A. J., Glennie M. J. Anti-idiotypic therapy for leukemias and lymphomas. Chemical Immunology 1990; 48: 126–166
   PubMed Web of Science ®Google Scholar
• Allebes W., Knops R., Herold M., Huber C., Haanen C., Capel P. Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine production. Leukemia Research 1991; 15: 215–222
   PubMed Web of Science ®Google Scholar
• Pizer B., Papanastassiou V., Hancock J., Cassano W., Coakham H., Kemshead J. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. British Journal of Haematology 1991; 11: 466–472
   Google Scholar
• Ota K., Ogawa N. Randomised controlled study of chemoimmunotherapy with Bestatin of acute non-lymphocytic Leukemia in adults. Biomedicine and Pharma-cotherapy 1990; 44: 93–101
   PubMed Web of Science ®Google Scholar
• Traczewska M., Chmielewska D., Ochocka M. Thymus factor X immunotherapy in children with acute lymphoblastic leukaemia during remission. Folia Haematolo-gica 1985; 112: 525–536
   PubMedGoogle Scholar
• DeNardo G. L., DeNardo S. J., O'Grady L. F., Mills S. L., Lewis J. P., Macey D. J. Radiation treatment of B cell malignancies with immunoconjugate. Frontaires in Radiation Therapy and Oncology 1990; 24: 194–201
   PubMedGoogle Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukaemia. Journal of Biological Response Modifiers 1988; 7: 97–113
   PubMedGoogle Scholar
• Bengtsson M., Simonsson B., Smedmyo B., et al. Immunostimulation post autologous bone marrow transplantation (ABMT) with the novel drug Linomide: Augmentation of T- and NIC-cell functions. Fifth Int. Symp. Autolog. Bone Marrow Transplant. 1990; 113: 234, Omaha, Nebraska
   Google Scholar
• Oldham R. K. Principles of Cancer Biotherapy. Raven Press, New York 1987
   Google Scholar
• Borrebaeck C., Larrick J. Therapeutic Monoclonal Antibodies. Stockton Press, London 1990
   Google Scholar
• Reif A. E., Mitchell M. S. Immunity to Cancer. Academic Press, Orlando, Florida 1985
   Google Scholar
• Daniels J. C., Serrou B., Rosenfeld C. Fundamental mechanisms in human cancer immunology. Elsevier, Amsterdam 1981
   Google Scholar
• Cramer D. V., Long G. S. LAK cell purging of bone marrow. Prog. Clin. Biol. Res. 1990; 333: 125–135
   PubMedGoogle Scholar
• Lattima E. C., Bykowsky M. J., Stutman O. Suspectibility to lysis by natural killer and natural cytotoxic cells is independent of the mitotic stage of the target cell cycle. Cell. Immunol. 1986; 100: 79–88
   PubMed Web of Science ®Google Scholar
• Lista P., Fierro M. T., Liao X. S., et al. LAK cells inhibit the clonogenic growth of human leukemic stem cells. Eur. J. Haematol 1989; 42: 425–430
   PubMed Web of Science ®Google Scholar
• Nasrallah A. G., Maile T. D. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res. 1983; 43: 4480–5585
   Google Scholar
• Tanaka Y. Natural killer activity in children with acute lymphoblastic leukemia. Hiroshima J. Med. Sci. 1981; 30: 127–133
   PubMed Web of Science ®Google Scholar
• Yamada S., Miyagawa Y., Kamiyana A., Akabane T. Analysis of Natural killer cell defects in childhood acute lymphoblastic leukemia. Japanese J. Clin. Oncol. 1984; 14: 75–80
   PubMed Web of Science ®Google Scholar
• Inada M., Okawa H., Suzuki M., Yata J. Natural killer activity as an indicator of relapse in acute leukemia. Japanese Journal of Clin. Oncol. 1984; 14: 335–345
   PubMed Web of Science ®Google Scholar
• Mageed A. A., Findley H. W., Franco C., et al. Natural killer cells in children with acute leukemia: the effect of Interleukin-2. Cancer 1987; 60: 2913–2918
   PubMed Web of Science ®Google Scholar
• Afify Z. A., Mageed A. A., Findley H. W., Ragab A. H. Cytotoxicity purified Leu 19 + cells from the peripheral blood of children with acute lymphoblastic leukemia. Cancer 1990; 66: 469–473
   PubMed Web of Science ®Google Scholar
• Tratkiewicz J. A., Szer J. Loss of natural killer activity as an indicator of relapse in acuje leukemia. Clin. E.xp. Immunol. 1990; 80: 241–246
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Cesano A., Guarini A., et al. Defective LAK cell generation and activity in acute Leukemia patients with active disease. Blood 1991; 78: 1041–1046
   PubMed Web of Science ®Google Scholar
• Zhou M. X., Findley H. W., Davis R., Ragab A. H. Assay of LAK activity generated from bone marrow cells of children with acute lymphoblastic leukemia. Blood 1990; 75: 160–165
   PubMed Web of Science ®Google Scholar
• Lim S. H., Worman C. P., Jewell A. P., Goldstone A. H. Cellular cytotoxic function and potential in acute myeloid leukemia. Leuk. Res. 1991; 15: 641–644
   PubMed Web of Science ®Google Scholar
• Ruco L. P., Procopio V., Macchilini A., et al. Severe deficiency of natural killer activity in the peripheral blood of patients with Hairy cell leukemia. Blood 1983; 61: 1132–1137
   PubMed Web of Science ®Google Scholar
• Fontana L., De Rossi G., Sanctis G. D., et al. Decreased natural killer activity in Hairy cell leukemia: an analysis at the cellular level. Blut 1986; 53: 107–113
   PubMedGoogle Scholar
• Smith B. R., Rosenthal D. S., Ault K. A. Natural killer lymphocytes in Hairy cell leukemia: presence of phenotypic-ally identifiable cells with defective functional activity. Exp. Hematol. 1985; 13: 189–193
   PubMed Web of Science ®Google Scholar
• Trentin L., Zambello R., Agostini C., et al. Mechanisms accounting for the defective natural killer activity in patients with Hairy cell leukemia. Blood 1990; 75: 1525–1530
   PubMed Web of Science ®Google Scholar
• Ziegler H. W., Kay N. E., Zerling J. M. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int. J. Cancer 1981; 21: 321–327
   Web of Science ®Google Scholar
• Foa R., Fierro M. T., Luso P., et al. Reduced natural killer T-cells in B-chronic lymphocytic Leukemia identified by 3 monoclonal antibodies: Leu-II, AIO, ABP28. Br. J. Haematol. 1986; 62: 151–154
   PubMed Web of Science ®Google Scholar
• Kay N. E., Perri R. T. Natural killer function in B-chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 343–345
   PubMedGoogle Scholar
• Lotzova E., Savary C. A., Poolock R. E., Fuchshuber P. Immunologic and clinical aspects of natural killer cells in human leukemia. Natural Immun. Cell Growth. Regul. 1990; 9: 173–181
   PubMedGoogle Scholar
• Apostolopoulos A., Symeonidis A., Zoumbos N. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukemia. Eur. J. Haematol 1990; 44: 39–44
   PubMed Web of Science ®Google Scholar
• Anderson R. W., Volsky D. J., Greenberg B., et al. Lymphocyte abnormalities in preleukemia. I. Decreased natural killer activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk. Res. 1983; 7: 389–395
   PubMed Web of Science ®Google Scholar
• Porzolt F., Heimpel H. Impaired T-cell and natural killer cell functions in patients with preleukemia. Blut 1982; 45: 243–248
   PubMedGoogle Scholar
• Okabe M., Minagawa T., Nakane A., et al. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes. Scand. J. Haematol 1986; 37: 111–117
   PubMedGoogle Scholar
• Sorskaar D., Forre O., Albertschtsen D., Stavem P. Decreased NK cell activity versus normal NK markers in mononuclear cells from patients with smoldering leukemia. Scand. J. Hematol. 1986; 37: 154–61
   PubMedGoogle Scholar
• Yataganas X., Eliopoulos G., Koulocheri S., et al. The effect of recombinant alpha-interferon on NK cell activity and clinical course in patients with myelodysplasia. Ann Hematol. 1991; 62: 225–229
   PubMed Web of Science ®Google Scholar
• Rajaram N., Tatake R. J., Advani S. H., et al. Natural killer and LAK cell functions in chronic myeloid leukemia. Cancer Immunol Immunolherapy 1990; 31: 44–48
   PubMed Web of Science ®Google Scholar
• Verfaillie C., Kay N., Miller W., McGlave P. Diminished LAK cell cytotoxicity and proliferation accompany disease progression in chronic myeloid leukemia. Blood 1990; 76: 401–408
   PubMed Web of Science ®Google Scholar
• Frydecka I. Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer 1985; 56: 2799–2807
   PubMed Web of Science ®Google Scholar
• Truaz T., Dokhelar M. C., Lipinski M., Amiel J. L. Low natural killer cell activity in patients with malignant lymphoma. Cancer 1982; 50: 2333–2339
   PubMed Web of Science ®Google Scholar
• Hawrylowicz C. M., Rees R. C., Hancock B. W., Potter C. W. Depressed spontaneous NK and interferon augmentation in patients with malignant lymphoma. Eur. J. Cancer Clin. Oncol. 1982; 18: 1081–1087
   PubMedGoogle Scholar
• Komiyawa A., Kawai H., Yamada S., et al. A killing defect of NK cells with the absence of NK cytotoxic factors in a child with Hodgkin's disease. Blood 1987; 69: 1686–1692
   PubMed Web of Science ®Google Scholar
• Levy S., Temple J. L., Aleksijevic A., et al. Depressed NK cell activity of peripheral blood mononuclear cells in untreated Hodgkin's disease; enhancing effect of interferon in vitro. Scand. J. Haematol. 1984; 33: 386–392
   PubMedGoogle Scholar
• Rajaram N., Tatake R. J., Advani S. H., Gangal S. G. Natural killer and LAK cell functions in Hodgkin's disease. Br. J. Cancer 1990; 62: 205–208
   PubMed Web of Science ®Google Scholar
• Barnett D., Wilson G. A., Lawrence A. C., Buckley G. A. The interleukin-2 receptor and its expression in acute leukemias and lymphoproliferative disorders. Dis Markers 1988; 6: 133–139
   PubMed Web of Science ®Google Scholar
• Sheibani K., Winberg C. D., Von de Velde S., et al. Distribution of lymphocytes with interleukin-2 (Tac antigenes) in reactive lympho-proliferative processes. Hodgkin's disease and non-Hodgkin's lymphoma. An immunohistologic study of 300 cases. Am. J. Pathol. 1987; 127: 27–37
   PubMed Web of Science ®Google Scholar
• Panayotides P., Lenjei R., Porwit A., Reizenstein P. Malignant B-cells have receptors for and respond to interleukin-2. Med. Oncol. Tumor Pharmacotherapy 1986; 3: 255–263
   PubMedGoogle Scholar
• Erber W. N., Mason D. Y. Expression of the interleukin-2 receptor (Tac antigen/CD25) in haematologic neoplasms. A. J. Clin. Pathol. 1988; 89: 645–648
   PubMed Web of Science ®Google Scholar
• Roselen A., Nakanishi M., Poplack D. G., et al. Expression of IL-2 receptor B subunit in haematologic malignancies. Blood 1989; 73: 1968–1972
   PubMed Web of Science ®Google Scholar
• Armitage R. J., Lai A. P., Roberts P. J., Cawley J. C. Certain myeloid cells possess receptors for interleukin-2. Br. J. Haematol. 1986; 64: 799–807
   PubMed Web of Science ®Google Scholar
• Brenner M. K. Interleukin-2 and the treatment of Leukemia and lymphoma. Leuk. Lymphoma 1991; 5: 77–83
   PubMed Web of Science ®Google Scholar
• Foa R., Caretto P., Fierro M. T., et al. Interleukin-2 does not promote the in vitro and in vivo proliferation and growth of human acute Leukemia cells of myeloid and lymphoid origin. Br. J. Haematol. 1990; 75: 34–40
   PubMed Web of Science ®Google Scholar
• Kimura H., Yamaguchi Y. Cytotoxic activity of various LAK cells against autologous lung Cancer, K562 and Daudi cells. Japanese J. Clin. Oncol. 1989; 19: 222–228
   PubMed Web of Science ®Google Scholar
• Bergmann L., Weidmann E., Bungert B., et al. Influence of various cytokines on the induction of LAK cells. Nat. Immun. Cell Growth Regul 1990; 9: 265–273
   PubMedGoogle Scholar
• Vehmeyer K., Scheurich P., Liersch T., Unger C. Immunomodulatory activity of hexadecylphosphocholine: mediated enhancement of T-cell response. Ann. Haematol. 1991; 62: A 110–85
   Google Scholar
• Vasilopoulos G., Sjogren A. M., Reizenstein P. Cytotoxic effects on viable human leukemic cells by combinations of LAK cells and monoclonal antibodies. Leuk. Res. 1989; 13: 87–91
   PubMed Web of Science ®Google Scholar
• Ehrke M. I., Maccubbin D., Ryoyamok K., et al. Correlation between adriamycin-induced augmentation of IL-2 production and of cell-mediated cytotoxicity in mice. Cancer Res. 1986; 46: 54–60
   PubMed Web of Science ®Google Scholar
• Kleinermann E. S. The enhancement of naturally occuring spontaneous monocyte-mediated cytotoxicity of cisplatin. Cancer Res. 1980; 40: 3099–3102
   PubMed Web of Science ®Google Scholar
• Mitchell M. S. Combining chemotherapy with biological response modifiers in treatment of cancer. J. Nat. Cancer Inst. 1988; 80: 1445–1450
   PubMed Web of Science ®Google Scholar
• Reissman T., Voegeli R., Hilgard P. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumour models. Cancer Immunol. Immunotheraphy 1989; 28: 179–184
   PubMed Web of Science ®Google Scholar
• Gronberg A., Ferm M., Tsai L., Kiessling R. Interferon-gamma is able to reduce tumour cell susceptibility to human LAK cells. Cell. Immunol. 1989; 118: 10–21
   PubMed Web of Science ®Google Scholar
• De Fries R. U., Golub S. H. Characteristics and mechanisms of IFN-gamma-induced protection of human tumour cells from lysis by LAK cells. J. Immunol. 1988; 140: 3686–3693
   PubMed Web of Science ®Google Scholar
• Han X., Itoh K., Balch C. M., Pellis N. R. lnterleukin-4 inhibits IL-2 induced activation of peripheral blood lymphocytes. Lymphokine Res. 1988; 7: 227–235
   PubMedGoogle Scholar
• Nagler A., Lanier L. L., Phillips J. H. The effects ofinterleukin-4 on human natural killer cells. J. Immunol. 1988; 141: 2349–2351
   PubMed Web of Science ®Google Scholar
• Lotozova E. The role of NK cells in immune surveillance against malignancies. Cancer Bull. 1984; 36: 215–225
   Google Scholar
• Blomaren H. Influence of low doses of an oxazaphosphochorine on NK activity of human lymphocytes. Cancer Immunol. Immunolherapy 1989; 29: 151–153
   PubMed Web of Science ®Google Scholar
• Hirano T. lnterleukin-6 and its receptor: their role in plasma cell neoplasms. Int. J. Cell Cloning 1991; 9: 166–184
   PubMedGoogle Scholar
• Lotzova E. Function of NK cells in various biological phenomena. Surv Synth. Pathol. Res. 1983; 2: 41–50
   Google Scholar
• Scarffe J. H. Emerging clinical uses for GM-CSF. Eur. J. Cancer 1991; 27: 1493–1504
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Bach F. H., Ochoa A. C. Augmentation of LAK activity in peripheral blood mono-nuclear cells activated with antiCD3 and IL-2. Preliminary results in ALL children. Cancer Immunol. Immunolherapy 1988; 27: 82–88
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M. Cytotoxicity of IL-2 activated lymphocytes for Leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Findley H. W., Mageed A. A., Nasr S. A., Ragab A. H. Interleukin-2 activates peripheral blood lymphocytes from children with ALL to kill autologous leukemic cells. Cancer 1988; 62: 1928–1931
   PubMed Web of Science ®Google Scholar
• Tahara T., Iseki R., Morishima Y., et al. Generation and characterisation of LAK cells against fresh human Leukemia cells. Japanese J. Cancer Res. 1988; 79: 390–399
   PubMedGoogle Scholar
• Fierro M. T., Liao X. S., Lusso P., et al. In vitro and in vivo susceptibility of human leukemic cells to LAK activity. Leuk. 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Tratkiewicz J. A., Szer J., Boyd R. L. LAK cytotoxicity against leukemic blast cells. Clin. Exp. Immunol. 1990; 80: 94–99
   PubMed Web of Science ®Google Scholar
• Teichmann J. V., Ludwig W. D., Seibt-Jung H., Thiel E. Induction of LAK cell against human Leukemia cells in vitro. Blut 1989; 59: 21–24
   PubMedGoogle Scholar
• Pais R. C., Ingrim N. B., Garcia M. L. Pharmacokinetics of recombinant IL-2 in children with malignancies: a pediatric oncology group study. J. Biol. Response Mod. 1990; 9: 517–521
   PubMedGoogle Scholar
• Lotzova E., Savary C. A. Interleukin-2 corrects defective NK activity of patients with leukemia. Comp. Immunol. Microbiol. Infect Dis. 1986; 9: 169–175
   PubMed Web of Science ®Google Scholar
• Jermy A., Jennings R., Lilleyman J. S., Rees R. C. Immunomodulation of NK activity in children with ALL. Eur. J. Cancer Clin. Oncol. 1987; 23: 1371–1377
   PubMedGoogle Scholar
• Mageed A. A., Findley H. W., Franco C., et al. Natural killer cells in children with acute leukemia: the effect of interleukin-2. Cancer 1987; 60: 2913–2918
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Schachner J. R., et al. Generation of cytotoxic NK cells in peripheral blood and bone marrow of AML patients after continuous infusion of interleukin-2. Am. J. Haematol. 1991; 37: 88–99
   PubMed Web of Science ®Google Scholar
• Van der Harst D., Brand A., Van Luxemberg Heys S. A. LAK cell functions in patients with leukaemic B-lymphoproliferative diseases. Blood 1989; 74: 2464–2470
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Raspadori D., et al. LAK cell activity in B- and T-chronic lymphocytic leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to LAK effectors. Blood 1990; 76: 1349–1354
   PubMed Web of Science ®Google Scholar
• Kay N. E., Zarling J. Restoration of impaired NK cell activity of B-chronic lymphocytic Leukemia patients by interleukin-2. Am. J. Hematol. 1987; 24: 161–167
   PubMed Web of Science ®Google Scholar
• Lotzova E. Possible application of NK cells and interleukin-2 in therapy of human leukemia. Prog. Clin. Biol. Res. 1987; 244: 259–266
   PubMedGoogle Scholar
• Verfaillie C., Miller W., Kay N., McGlave P. Adherent LAK cells in chronic myeloid leukemia: a benign population with potent cytotoxic activity. Blood 1989; 74: 793–797
   PubMed Web of Science ®Google Scholar
• Somasundaram R., Advani S. H., Gangal S. G. Propagation of cytotoxic effectors from chronic Leukemia patients and cloning if cytotoxic T-cells. Cancer Immunol. Immunotherapy 1988; 27: 183–189
   PubMed Web of Science ®Google Scholar
• Pawalec G., Ehninger G., Schmidt H., et al. Susceptibility of autologous target cells to lysis by LAK effectors from interferon-alpha-treated chronic myeloid leukemia. Cancer Immunol. Immunotherapy 1990; 32: 167–172
   PubMed Web of Science ®Google Scholar
• Trentin L., Zambello R., Agostini C., et al. Mechanisms accounting for the defective NK activity in patients with Hairy cell leukemia. Blood 1990; 75: 1525–1530
   PubMed Web of Science ®Google Scholar
• Trentin L., Ambrosetti A., Zambello R., et al. Alpha-interferon activated cytotoxic lymphocytes in Hairy cell Leukemia patients: evaluation of cytotoxic events. Leuk. Res. 1987; 11: 843–847
   PubMed Web of Science ®Google Scholar
• Hooper W. C., Barth R. F., Shah N. T. Lack of NK cell activity in Hairy cell Leukemia patients and partial restoration with IL-2. Cancer 1986; 57: 988–993
   PubMed Web of Science ®Google Scholar
• Lahat N., Aghai E., Kotler A., et al. Discordent effect of alpha-interferon on natural killer activity and tumour cell sensitivity to lysis in Hairy cell leukemia. Blood 1988; 71: 1141–1143
   PubMed Web of Science ®Google Scholar
• Semenzato G., Pizzolo G., Agostini G., et al. Alpha-interferon activates the NK system in patients with Hairy cell leukemia. Blood 1986; 68: 293–296
   PubMed Web of Science ®Google Scholar
• Mehta B. A., Satam M. N., Advani S. H., Nadkarni J. J. In vitro modulation of NK cell activity in Non-Hodgkin's lymphoma patients after therapy. Cancer Immunol. Immunotherapy 1989; 28: 148–152
   PubMed Web of Science ®Google Scholar
• Benoist H., Madoulet C., Jardillier J. C., Desplaces A. Adriamycin induced resistance of sensitive K562 cells to NK lymphocytes attack. Cancer Immunol. Immunolherapy 1985; 20: 128–135
   Google Scholar
• Oldham R. Biotherapy: The 4th modality of Cancer therapy. J. Cell. Physiol. Suppl. 1986; 4: 91–99
   PubMedGoogle Scholar
• Dinota A., Gobbi M., Tazzari P. L., Raspadori D., Bontadini A., Lauria F., Foa R., Tura S. A sensitive test for the detection of NK activity. Plasma clot clonogenic assay. J. Immunol. Methods. 1988; 114: 53–59
   PubMed Web of Science ®Google Scholar
• Bradley E. C., Catino J. J., Issell B. F., Poiest B., Hustad J. J., Dalton T., Allegretta M., Mier J. Cell-mediated inhibition of tumor colony formation in agarose by resting and interleukin-2 stimulated human lymphocytes. Cancer Res. 1985; 45: 1464–1468
   PubMed Web of Science ®Google Scholar
• Heo D. S., Park J.-G., Hata K., Day R., Herberman R. B., Whiteside T. L. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 1990; 50: 3681–3690
   PubMed Web of Science ®Google Scholar
• Nomori H., Saijo N., Fujita J., Hyoi H., Sasaki Y., Shimizu E., Kanzawa F., Inomata M., Hoshi A. Detection of NK activity and antibody-dependent cellular cytotoxicity of lymphocytes by human tumor clonogenic assay. Its correlation with the 51Cr-release assay. Int. J. Cancer 1985; 35: 449–455
   PubMed Web of Science ®Google Scholar
• Scuderi P., Woo L., Chong A. S. F., Liu R., Salmon S. E. Modification of the clonogenic assay for the detection of lymphokine activated killer cell activity. J. Immunol. Methods 1990; 128: 119–126
   PubMed Web of Science ®Google Scholar
• Echarti C., Maurer H. R. Lymphokine-activated killer cells: determination of their tumour cytolytic capacity by a clonogenic micro-assay using agar capillaries. J. Immunol. Methods 1991; 143: 41–47
   PubMed Web of Science ®Google Scholar
• Maurer H. R., Echarti C. Effects of low-dose mafosfamide on the lymphokine-activated killer cell activity of peripheral blood mononuclear cells determined by a clonogenic microassay. Ann. Haematoi. 1991; 63: 79–83
   PubMed Web of Science ®Google Scholar
• North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J. Exp. Med. 1982; 55: 1063–1074
   Web of Science ®Google Scholar